L-Arginine supplementation in sepsis: Beneficial or harmful?

Current Opinion in Critical Care

Volumn 12, Issue 4, 2006, Pages 303-308

  Kalil, Andre C ^a,c   Danner, Robert L ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Enteral; L arginine; Parenteral; Sepsis; Septic shock; Severe sepsis

Indexed keywords

ARGININE; NITRIC OXIDE;

AMINO ACID METABOLISM; CLINICAL PRACTICE; CONCENTRATION RESPONSE; DIET; DOG; DRUG EFFICACY; HAZARD ASSESSMENT; HUMAN; IMMUNITY; IMMUNOLOGY; MONOTHERAPY; NONHUMAN; NUTRITIONAL SUPPORT; PARENTERAL NUTRITION; PHYSIOLOGY; REVIEW; SAFETY; SEPSIS; SEPTIC SHOCK; SUPPLEMENTATION; SURVIVAL;

ANIMALS; ARGININE; DIETARY SUPPLEMENTS; HUMANS; SEPSIS;

EID: 33746096538     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000235206.92697.bf     Document Type: Review

References (54)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554.
2. Luiking YC, Poeze M, Dejong CH, et al. Sepsis: an arginine deficiency state? Crit Care Med 2004; 32:2135-2145.
3. Kilbourn RG, Goldfarb RD. Can nitric oxide production be modulated by altering L-arginine levels? Crit Care Med 1999; 27:2586-2587.
4. Boger RH, Bode-Boger SM. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol 2001; 41:79-99.
5. Morris SM Jr. Arginine metabolism in vascular biology and disease. Vasc Med 2005; 10(suppl 1):S83-S87.
6. Zaloga GP, Siddiqui R, Terry C, Marik PE. Arginine: mediator or modulator of sepsis? Nutr Clin Pract 2004; 19:201-215.
7. Chiarla C, Giovannini I, Siegel JH. Plasma arginine correlations in trauma and sepsis. Amino Acids 2006; 30:81-86. Plasma levels of arginine were compared with other amino acids in trauma and sepsis. Changes in arginine in trauma and sepsis were correlated with changes in other amino acids, mainly lysine, and a lower arginine level was observed in trauma compared to sepsis.
8. Ochoa JB, Makarenkova V, Bansal V. A rational use of immune enhancing diets: when should we use dietary arginine supplementation? Nutr Clin Pract 2004; 19:216-225.
9. Gardiner KR, Gardiner RE, Barbul A. Reduced intestinal absorption of arginine during sepsis. Crit Care Med 1995; 23:1227-1232.
10. Heys S, Gardner E. Nutrients and the surgical patient: current and potential therapeutic applications to clinical practice. J R Coll Surg Edinb 1999; 44:283-293.
11. Castillo L, Sanchez M, Vogt J, et al. Plasma arginine, citrulline, and ornithine kinetics in adults, with observations on nitric oxide synthesis. Am J Physiol Endocrinol Metab 1995; 268:E360-E367.
12. Argaman Z, Young VR, Noviski N, et al. Arginine and nitric oxide metabolism in critically ill septic pediatric patients. Crit Care Med 2003; 31:591-597.
13. Reade MC, Clark MF, Young JD, Boyd CA. Increased cationic amino acid flux through a newly expressed transporter in cells overproducing nitric oxide from patients with septic shock. Clin Sci (Lond) 2002; 102:645-650.
14. Schwartz D, Schwartz IF, Gnessin E, et al. Differential regulation of glomerular arginine transporters (CAT-1 and CAT-2) in lipopolysaccharide-treated rats. Am J Physiol Renal Physiol 2003; 284:F788-F795.
15. Nijveldt RJ, Teerlink T, Van Der Hoven B, et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22:23-30.
16. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20:2032-2037.
17. Nijveldt RJ, Teerlink T, van Leeuwen PA. The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr 2003; 22:99-104.
18. Berkels R, Taubert D, Grundemann D, Schomig E. Agmatine signaling: odds and threads. Cardiovasc Drug Rev 2004; 22:7-16.
19. Raghavan SA, Dikshit M. Vascular regulation by the L-arginine metabolites, nitric oxide and agmatine. Pharmacol Res 2004; 49:397-414.
20. Satriano J. Agmatine: at the crossroads of the arginine pathways. Ann N Y Acad Sci 2003; 1009:34-43.
21. Satriano J, Schwartz D, Ishizuka S, et al. Suppression of inducible nitric oxide generation by agmatine aldehyde: beneficial effects in sepsis. J Cell Physiol 2001; 188:313-320.
22. Bruins MJ, Soeters PB, Lamers WH, et al. L-arginine supplementation in hyperdynamic endotoxemic pigs: effect on nitric oxide synthesis by the different organs. Crit Care Med 2002; 30:508-517.
23. Lorente JA, Delgado MA, Tejedor C, et al. Modulation of systemic hemodynamics by exogenous L-arginine in normal and bacteremic sheep. Crit Care Med 1999; 27:2474-2479.
24. Lorente JA, Landin L, De Pablo R, et al. L-arginine pathway in the sepsis syndrome. Crit Care Med 1993; 21:1287-1295.
25. Giugliano D, Marfella R, Verrazzo G, et al. The vascular effects of L-Arginine in humans. The role of endogenous insulin. J Clin Invest 1997; 99:433-438.
26. Hecker M, Sessa WC, Harris HJ, et al. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci USA 1990; 87:8612-8616.
27. Chowdhary S, Nuttall SL, Coote JH, Townend JN. L-arginine augments cardiac vagal control in healthy human subjects. Hypertension 2002; 39:51-56.
28. Yeh CL, Lee CH, Chen SC, et al. Effects of arginine-containing total parenteral nutrition on N balance and phagocytic activity in rats undergoing a partial gastrectomy. Br J Nutr 2005; 93:267-272. The effects of arginine-containing parenteral nutrition on phagocytic activity were studied in rats undergoing gastrectomy. Parenterally arginine enhanced phagocytic activity and reduced the production of inflammatory mediators at the site of injury, but arginine supplementation did not influence the secretion of anabolic hormones or nitrogen balance.
29. -.
30. Shang HF, Hsu CS, Yeh CL, et al. Effects of arginine supplementation on splenocyte cytokine mRNA expression in rats with gut-derived sepsis. World J Gastroenterol 2005; 11:7091-7096. The effects of arginine-enriched diets before sepsis and/or arginine-containing total parenteral nutrition after sepsis on cytokine mRNA expression levels were evaluated in splenocytes of rats with gut-derived sepsis. The arginine administration significantly enhanced the mRNA expression levels of Th1 and Th2 cytokines.
31. Sato N, Moore FA, Smith MA, et al. Immune-enhancing enteral nutrients differentially modulate the early proinflammatory transcription factors mediating gut ischemia/reperfusion. J Trauma 2005; 58:455-461. L-Arginine and glutamine were studied in an ischemia/reperfusion model to evaluate the activation of the early proinflammatory transcription factors. Arginine and glutamine had no differential effect on nuclear factor-κB, whereas activator protein-1 expression (c-jun but not c-fos) was markedly increased by arginine and significantly decreased by glutamine.
32. Alexander JW, Metze TJ, McIntosh MJ, et al. The influence of immunomodulatory diets on transplant success and complications. Transplantation 2005; 79:460-465. Adult renal transplant patients receiving standard immunosuppression were randomized to receive or not receive supplemental arginine and canola oil (containing both ω-3 and ω-9 fatty acids) twice daily. Fewer rejection episodes, cardiac events, and episodes of sepsis, and less new-onset diabetes mellitus, were observed in the supplement compared to the control group.
33. Gianotti L, Alexander JW, Pyles T, Fukushima R. Arginine-supplemented diets improve survival in gut-derived sepsis and peritonitis by modulating bacterial clearance The role of nitric oxide. Ann Surg 1993; 217:644-653.
34. Peck MD, Babcock GF, Alexander JW, et al. High doses of dietary arginine during repletion impair weight gain and increase infectious mortality in protein-malnourished mice. Br J Nutr 1995; 74:787-795.
35. Gennari R, Alexander JW. Arginine, glutamine, and dehydroepiandrosterone reverse the immunosuppressive effect of prednisone during gut-derived sepsis. Crit Care Med 1997; 25:1207-1214.
36. Madden HP, Breslin RJ, Wasserkrug HL, et al. Stimulation of T cell immunity by arginine enhances survival in peritonitis. J Surg Res 1988; 44:658-663.
37. Yeh CL, Yeh SL, Lin MT, Chen WJ. Effects of arginine-enriched total parenteral nutrition on inflammatory-related mediator and T-cell population in septic rats. Nutrition 2002; 18:631-635.
38. Gonce SJ, Peck MD, Alexander JW, Miskell PW. Arginine supplementation and its effect on established peritonitis in guinea pigs. JPEN J Parenter Enteral Nutr 1990; 14:237-244.
39. Saito H, Trocki O, Wang SL, et al. Metabolic and immune effects of dietary arginine supplementation after burn. Arch Surg 1987; 122:784-789.
40. Wiel E, Pu Q, Corseaux D, et al. Effect of L-arginine on endothelial injury and hemostasis in rabbit endotoxin shock. J Appl Physiol 2000; 89:1811-1818.
41. Pastor C, Teisseire B, Vicaut E, Payen D. Effects of L-arginine and L-nitro-arginine treatment on blood pressure and cardiac output in a rabbit endotoxin shock model. Crit Care Med 1994; 22:465-469.
42. Heyland DK, Samis A. Does immunonutrition in patients with sepsis do more harm than good? Intens Care Med 2003; 29:669-671.
43. Heyland DK, Novak F, Drover JW, et al. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001; 286:944-953.
44. Galban C, Montejo JC, Mesejo A, et al. An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients. Crit Care Med 2000; 28:643-648.
45. Atkinson S, Sieffert E, Bihari D. A prospective, randomized, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill Guy's Hospital Intensive Care Group. Crit Care Med 1998; 26:1164-1172.
46. Bower RH, Cerra FB, Bershadsky B, et al. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med 1995; 23:436-449.
47. Caparros T, Lopez J, Grau T. Early enteral nutrition in critically ill patients with a high-protein diet enriched with arginine, fiber, and antioxidants compared with a standard high-protein diet The effect on nosocomial infections and outcome. JPEN J Parenter Enteral Nutr 2001; 25:299-308.
48. Dent D, Heyland D, Levy H. Immunonutrition may increase mortality in critically ill patients with pneumonia: results of a randomized trial. Crit Care Med 2003; 30:A17.
49. Bertolini G, Iapichino G, Radrizzani D, et al. Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intens Care Med 2003; 29:834-840.
50. Kieft H, Roos AN, van Drunen JD, et al. Clinical outcome of immunonutrition in a heterogeneous intensive care population. Intens Care Med 2005; 31:524-532. A total of 597 ICU patients expected to require enteral tube feeding for more than 2 days were randomized to receive immunonutrition or an isocaloric control formula. Immunonutrition had no beneficial effect on clinical-outcome parameters.
51. Schulman AS, Willcutts KF, Claridge JA, et al. Does the addition of glutamine to enteral feeds affect patient mortality? Crit Care Med 2005; 33:2501-2506. The addition of glutamine to standard feeds showed no more benefits than standard feeds alone, or an IED formula.
52. Lerman A, Burnett JC Jr, Higano ST, et al. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998; 97:2123-2128.
53. Blum A, Porat R, Rosenschein U, et al. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris. Am J Cardiol 1999; 83:1488-1490; A1488.
54. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295:58-64. A total of 153 patients following a first ST-segment elevation myocardial infarction were randomized to receive L-arginine (the goal dose was 3 g three times a day) or matching placebo for 6 months. L-Arginine did not improve vascular stiffness measurements or ejection fraction and was significantly associated with higher post-infarction mortality.